GTCBio’s 6th Annual Cancer Drugs Research and Development Conference on February 19-20, 2009 in Philadelphia, PA will provide an extensive look at the successes as well as the challenges that face modern cancer drug development and provide you with an update on cancer drugs currently in development through clinical trials. A look at novel compounds and emerging targets will prime you with the future direction of cancer drugs with key topics to be discussed by leading experts including mTOR inhibitors, angiogenesis, PI3K inhibitors, rapamycin analogs, PARP inhibitors, VEGF Receptor inhibitors, and much more. The new frontier of combination therapeutics and therapies will be also covered in detail. Sign up now as space is limited!

Conference Sessions:

- Challenges and Successes of Modern Cancer Drugs
- Cancer Drug Discovery Strategies
- Novel Compounds and Emerging Targets
- Combination Therapies for Cancer Treatment
- Cancer Drugs in Clinical Trials

Distinguished Speaker Include:

Beverly Packard, President, OncoImmunin, Inc.
Kunwar Shailubhai, CSO, Callisto Pharmaceuticals, Inc.
George Blumenschein, MD Anderson Cancer Center
Jeffery Schlom, Chief, Laboratory of Tumor Immunology and Biology, NIH/NCI
Xuesong Liu, Principle Investigator, Abbott Laboratories
Dinah Sah, Senior Director, Research, Alnylam Pharmaceuticals
Guillerno Morales, Director, Chemistry, Semafore Pharmaceuticals
John Martens, Senior Scientist, Department of Medical Oncology, Erasmus Medical Center
Nathalie Scholler, Assistant Professor, University of Pennsylvania
Domagoj Vucic, Scientist, Protein Engineering, Genentech
Daniel Powell, Deputy Director Cell & Vaccine Production Facility, University of Pennsylvania
Anne Ree, Professor of Oncology, University of Oslo, Norwegian Radium Hospital